

Appendix

Potential target patient populations 2020

Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience


Immunology

Herceptin + Perjeta, Tecentriq: *HER2+ early Breast Cancer (eBC)*




Perjeta, Herceptin, Kadcylla, Tecentriq: HER2+ metastatic Breast Cancer (mBC)

- The target US and EU 5 population for **1L HER2+ mBC** is **~19,500 patients (7,700 de novo and 11,800 adjuvant relapse)**
- The target US and EU 5 population for **2L-4L HER2+ mBC** is **~28,200 patients (~11,400 US/~16,800 Top 5 EU)**




	Adjuvant Relapse	de novo
1L Patients (Top 5 EU)	5,400	3,700
1L Patients (US)	4,900	4,000
	HER2+ Rx opportunities Drug treated patients	
	US	5 EU
1L	4,900	5,400
2L	6,000	7,600
3L	3,700	5,700
4L	1,500	3,600

Ipatasertib, SERD (RG6171, GDC-9545): *HER2-/HR+ 1L and recurrent mBC*




Source: Roche/Genentech; *2/3L includes HR+ patients who received chemotherapy in 1L; Patients may receive up to 7 lines of treatment, but 4L+ patients are not included; Ipatasertib in collaboration with Array BioPharma

Tecentriq, ipatasertib: Triple Negative Breast Cancer (TNBC)




Avastin: Ovarian Cancer (OC)




Tecentriq:

Adjuvant squamous cell carcinoma of the head and neck (SCCHN)




Source: Roche/Genentech

Tecentriq, Avastin, tiragolumab: Non Squamous Non Small Cell Lung Cancer (NSq NSCLC)




Rozlytrek (ROS1+) and Gavreto (RET+): *ROS1+ or RET+ metastatic non-small cell lung cancer (mNSCLC)*




Alecensa:

ALK+ metastatic Non Small Cell Lung Cancer (mNSCLC)




Tecentriq, tiragolumab: Small Cell Lung Cancer (SCLC)




Zelboraf:

Adjuvant BRAF+ stage IIc and III Melanoma




Zelboraf:

1L BRAF+ metastatic Melanoma (mM)




Erivedge: *Advanced Basal Cell Carcinoma (BCC)*




Avastin: Colorectal Cancer (CRC)

- The target population for Avastin in 1L CRC is ~238,200 patients and in 2L CRC ~128,300 patients




Tecentriq:


Metastatic Urothelial Bladder Cancer (mUBC)



Tecentriq: Renal Cell Carcinoma (RCC)




Tecentriq, Avastin: Hepatic Cell Carcinoma (HCC)




Tiragolumab:

Esophageal squamous cell carcinoma (ESCC)




Ipatasertib


Metastatic castration-resistant prostate cancer (mCRPC)




Gazyva, MabThera/Rituxan: Indolent Non-Hodgkin's Lymphoma (iNHL)




Polivy, MabThera/Rituxan: Aggressive Non-Hodgkin's Lymphoma (aNHL/DLBCL)



Gazyva, Venclexta, MabThera/Rituxan: Chronic Lymphocytic Leukemia (CLL)




Venclexta: Acute Myeloid Leukemia (AML)



Source: Roche/Genentech; Venclexta in collaboration with AbbVie

Venclexta: Multiple Myeloma (MM)



Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Hemlibra: *Hemophilia A*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Faricimab, Port Delivery System (PDS), Lucentis: *Age-related Macular Degeneration (AMD)*




Faricimab, Port Delivery System (PDS), Lucentis: *Diabetic Macular Edema (DME)*



Port Delivery System (PDS), Lucentis: *Retinal Vein Occlusion (RVO)*



RG6312, RG6147, RG6299*: *Geographic Atrophy (GA)*



Source: Roche/Genentech; * Study conducted by Ionis, Roche has option to in-license

Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience

Immunology

Xofluza: Influenza A & B



Oncology

Hemophilia A


Ophthalmology

Infectious diseases


Neuroscience

Immunology


Ocrevus, fenebrutinib: Multiple Sclerosis (MS)




Ervysdi (risdiplam): *Spinal Muscular Atrophy (SMA)*




Myostatin inhibiting adnectin fusion protein (RG6206): *Duchenne Muscular Dystrophy (DMD)*




Tominersen (HTT-ASO, RG6042): *Huntington's Disease (HD)*




Gantenerumab, semorinemab: *Alzheimer's Disease (AD)*




Enspryng (satralizumab, RG6168): *Neuromyelitis Optica (NMO)*



Prasinezumab (RG7935): *Parkinson's Disease (PD)*



Crovalimab (RG6107, SKY59): *Paroxysmal Nocturnal Hemoglobinuria (PNH)*



Oncology

Hemophilia A


Ophthalmology

Infectious diseases

Neuroscience


Immunology

rhPentraxin-2; Esbriet: *Idiopathic Pulmonary Fibrosis (IPF)*




Xolair:

Moderate to severe Asthma




Xolair: *Nasal Polyps*




Xolair:

Chronic idiopathic urticaria (CIU)





Xolair: *Food allergy*




Actemra, MabThera/Rituxan: Rheumatoid Arthritis (RA)

Global target population for Actemra and MabThera/Rituxan in rheumatoid arthritis is ~1.3M biologics eligible patients.

US Biologic treated patients by line of therapy




Actemra: Systemic Juvenile Idiopathic Arthritis (sJIA)




Actemra:


Polyarticular Juvenile Idiopathic Arthritis (pJIA)




Actemra: Giant Cell Arteritis (GCA)



Etrolizumab: *Crohn's Disease (CD)*



Gazyva: *Lupus Nephritis (LN)*



Doing now what patients need next